Intec Pharma Ltd Company Profile (NASDAQ:NTEC)

Analyst Ratings

Consensus Ratings for Intec Pharma Ltd (NASDAQ:NTEC) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.25 (80.66% upside)

Analysts' Ratings History for Intec Pharma Ltd (NASDAQ:NTEC)
Show:
DateFirmActionRatingPrice TargetActions
4/5/2016Maxim GroupReiterated RatingBuy$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/16/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Intec Pharma Ltd (NASDAQ:NTEC)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Intec Pharma Ltd (NASDAQ:NTEC)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.34)($0.34)($0.34)
Q2 20161($0.34)($0.34)($0.34)
Q3 20161($0.34)($0.34)($0.34)
Q4 20161($0.35)($0.35)($0.35)
Q1 20171($0.35)($0.35)($0.35)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.31)($0.31)($0.31)
Q4 20171($0.31)($0.31)($0.31)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intec Pharma Ltd (NASDAQ:NTEC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Intec Pharma Ltd (NASDAQ:NTEC)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Intec Pharma Ltd (NASDAQ:NTEC)
DateHeadline
07/02/16 08:18 AMIndian student warns his countrymen over fraudulent paperwork
06/03/16 08:23 AMIntec Pharma Names Nir Sassi CFO, Effective Aug. 1, Succeeding Oren Mohar - Intec Pharma Ltd. (NTEC), a clinical stage biopharmaceutical company, announced Friday that it has appointed Nir Sassi, the Company's VP Finance, as the Chief Financial Officer of the company effective as of August 1. Sassi replaces Oren Mohar, who has ...
06/03/16 08:23 AMIntec Pharma Announces Planned Management Changes - Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that Mr. Oren Mohar, the company's Chief Financial Officer ...
05/31/16 07:42 AMIntec Pharma Receives Approval for US$5.2 Million Grant - [at noodls] - JERUSALEM, May 31, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary drug delivery platform ...
05/16/16 12:09 PMIntec Pharma Nominates John Kozarich As Chairman Of Board - Quick Facts - (RTTNews.com) - Intec Pharma Ltd. ( NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary drug delivery platform technology, the Accordion Pill, said that its board of directors has nominated Dr. John ...
05/16/16 07:42 AMIntec Pharma to Nominate Dr. John W. Kozarich as Chairman of the Board of Directors - [at noodls] - JERUSALEM, May 16, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary drug delivery platform ...
05/03/16 07:10 AMIntec Pharma Appoints VP of Clinical and Regulatory Affairs - [at noodls] - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the appointment of Pnina Strauss-Levy as Vice President, Clinical and Regulatory Affairs. ... ...
04/11/16 03:07 AMIntec Pharma Enrolls First Patient in Pivotal Phase III Clinical Trial of AP-CDLD for Advanced Parkinson’s Disease Patients - [at noodls] - JERUSALEM, Israel, April 6, 2016/PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion ...
04/06/16 07:10 AMIntec Pharma Expands Intellectual Property for AP-CDLD with Patent in South Korea - [at noodls] - JERUSALEM, Israel, April 6, 2016/PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion ...
04/05/16 10:54 AMCYTR Awaits Data In June, GILD Gets FDA Nod, PGNX Will Have To Wait - GMXAY.OB closed Monday's trading at $70.74, up 0.67%. Intec Pharma Ltd.'s (NTEC) pivotal phase III trial of AP-CDLD for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients has enrolled the first patient. The study is ...
04/04/16 07:07 AMIntec Pharma Enrolls First Patient in Pivotal Phase III Clinical Trial of AP-CDLD for Advanced Parkinson's Disease Patients - [at noodls] - JERUSALEM, April 4, 2016/PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the enrollment in the U.S. of the first patient in its ...
03/19/16 10:19 AMIntec Pharma : Mr. Zvika Joseph to Step Down as Chairman of the Board of Directors - JERUSALEM, ISRAEL--(Marketwired - Mar 17, 2016) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that Mr ...
03/17/16 12:04 PMINTEC PHARMA LTD. Financials -
03/17/16 09:30 AMMr. Zvika Joseph to Step Down as Chairman of the Board of Directors - [Marketwired] - Intec Pharma Ltd. , a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that Mr. Zvika Joseph has resigned ...
03/14/16 06:45 AMIntec Pharma Reports 2015 Fourth Quarter and Full-Year Financial Results - [Marketwired] - Intec Pharma Ltd. , an Israeli clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced its financial results for ...
03/14/16 06:30 AMIntec Pharma Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website - [Marketwired] - Intec Pharma Ltd. , a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that its annual report on Form 20-F, ...
03/14/16 06:15 AMIntec Pharma Ltd.: Notice of Special General Meeting of Shareholders - [Marketwired] - Notice is hereby given that the special general meeting of shareholders of Intec Pharma Ltd. , will be held at the offices of Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co., One Azrieli Center, Round ...
03/10/16 10:22 AMActive Stocks Climbing Strong – PULM, HTGM, SHIP, NTEC, SYX, DWCH, BPI - Intec Pharma Ltd (NTEC) traded at $4.30 + 0.37 (9.41 pct). The company is +18.73 pct in the last four weeks, -19.78 pct year-to-date, and +977.50 pct during the past four quarters. Systemax Inc. (SYX) traded at $8.90 + 1.44 (19.30 pct). The company is +6 ...
03/10/16 07:11 AM8:11 am Intec Pharma completes Phase 1 clinical trial with third pipeline product -
03/10/16 07:00 AMIntec Pharma Completed a Phase I Clinical Trial With Its Third Pipeline Product - [Marketwired] - Intec Pharma Ltd. , a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has completed a Phase I clinical ...
03/07/16 10:20 AMCompany Overview of Intec Pharma Ltd. - Intec Pharma Ltd., a drug development company, develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill, in Israel. The Accordion Pill, a novel gastro-retentive delivery system improves the pharmacokinetics and ...
01/28/16 09:35 AMIntec Pharma Ltd. (NTEC) - Intec Pharma Ltd., a drug development company, develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill, in Israel. The Accordion Pill, a novel gastro-retentive delivery system improves the pharmacokinetics and ...
01/05/16 06:00 AMIntec Pharma to Present at Biotech Showcase 2016 - [Marketwired] - Intec Pharma Ltd. , a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that its Chief Executive Officer, ...
12/16/15 09:59 AMIntec Pharma Further Expands Intellectual Property with a New Patent for the Accordion Pill Zaleplon in Europe - [at noodls] - JERUSALEM, ISRAEL - (Dec 16, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform ...
12/14/15 09:14 AMIntec Pharma Receives an IRB Approval to initiate Phase III Clinical Trial of AP – CDLD for the Treatment of Parkinson’s Disease - [at noodls] - JERUSALEM, ISRAEL - (December 14, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform ...
12/14/15 07:09 AMIntec Pharma Receives an IRB Approval to Initiate Phase III Clinical Trial of AP - CDLD for the Treatment of Parkinson's Disease - [Marketwired] - Intec Pharma Ltd. , a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has received a US centralized ...
12/09/15 06:08 AMEntering Phase I clinical trial with our third pipeline product - [at noodls] - JERUSALEM, ISRAEL - (December 8, 2015) - Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform ...
12/08/15 07:30 AMIntec Pharma Enters Phase I Clinical Trial With Its Third Pipeline Product - [Marketwired] - Intec Pharma Ltd. , a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it is entering a Phase I clinical ...
11/05/15 03:30 PMIntec Pharma Reports Results for the Third Quarter of 2015 - [Marketwired] - Intec Pharma Ltd. , an Israeli clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced its financial results for ...
10/22/15 07:30 AMIntec Pharma Expands Intellectual Property With a New Patent for the Accordion Pill in Europe - [Marketwired] - Intec Pharma Ltd. , a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the Company has been informed ...
10/12/15 08:37 PMIntec Pharma Announces Topline Results of a Food Effect, Pharmacokinetic Study of AP-CDLD 50/500mg for the Treatment of Parkinson's Disease Symptoms - [Marketwired] - Intec Pharma Ltd. , a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced results of the food effect study ...
09/17/15 04:58 PMIntec Pharma Ltd. Announces Partial Exercise of Underwriters Option to Purchase Additional Ordinary Shares - [Marketwired] - Intec Pharma Ltd. , a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the underwriters of its previously ...
08/14/15 09:51 AMIntec Pharma Ltd. Announces Closing of U.S. Initial Public Offering - [at noodls] - Har Hotzvim, Jerusalem, Israel, August 7, 2015 - Intec Pharma Ltd. (the 'Company') (NASDAQ: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion ...
08/06/15 04:40 AMIntec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering - [at noodls] - Har Hotzvim, Jerusalem, Israel, August 4, 2015 - Intec Pharma Ltd. (the 'Company') (NASDAQ: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion ...

Social

About Intec Pharma Ltd

Intec Pharma Ltd logoIntec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson's disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NTEC
  • CUSIP:
Key Metrics:
  • Previous Close: $4.97
  • 50 Day Moving Average: $4.54
  • 200 Day Moving Average: $4.11
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $58.61M
  • Current Year EPS Consensus Estimate: $-1.48 EPS
  • Next Year EPS Consensus Estimate: $-1.40 EPS
Additional Links:
Intec Pharma Ltd (NASDAQ:NTEC) Chart for Saturday, July, 30, 2016